Robert Greenfield
Cardiovascular Disease · Fountain Valley, CANPI 1649307000
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,174 of the $26,978 with a category attached, or 71.1%. 30 manufacturers reported payments, led by Amgen at 57.4% of the total. Reporting peaked in 2019 at $20,810 and has fallen 95.3% since, to $977 in 2024. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $183.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- Sanofi-aventis U.S. LLC$4K
- Regeneron Healthcare Solutions, Inc.$4K
- Medtronic$930
- Novartis$500
- Boehringer Ingelheim$190
- plus $2K from 24 others
What the payments were for
- Consulting fees$2,5009%
- Speaking & faculty fees$19,17471%
- Travel & lodging$5052%
- Food & beverage$4,77618%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $15,489 |
| Sanofi-aventis U.S. LLC | 19 | $4,336 |
| Regeneron Healthcare Solutions, Inc. | 10 | $3,848 |
| Medtronic | 7 | $930 |
| Novartis | 19 | $500 |
| Boehringer Ingelheim | 4 | $190 |
| Kowa Pharmaceuticals America, Inc. | 1 | $188 |
| AstraZeneca | 8 | $186 |
| Esperion Therapeutics, Inc. | 4 | $166 |
| Johnson & Johnson | 10 | $155 |
| Amarin Pharma, Inc. | 3 | $142 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $137 |
| Novo Nordisk | 2 | $131 |
| Regeneron | 1 | $122 |
| Pfizer | 5 | $84 |
| Kestra Medical Technology Services, Inc. | 1 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Bardy Diagnostics, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Bayer | 1 | $23 |
| Merck | 1 | $23 |
| Aegerion Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Teleflex LLC | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Gilead | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Travere Therapeutics, Inc. | 4 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,978 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Fountain Valley
- Bao BuiFountain Valley$430K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.